Myeloid leukemia
Drug research and approvals for myeloid leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 680 studies of myeloid leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 114 drug trials for it since 2013, and FDA has 37 approved and 169 open orphan designations naming it.
- Recruiting worldwide: 680
- Trials authorized in Canada: 114
- FDA orphan approvals: 37
- EU medicines: 0
Recruiting Now
Newest start dates first, of 680 recruiting on ClinicalTrials.gov ↗- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for…NCT06930352 · Phase 2 · Uma Borate · starts Jan 15, 2027
- A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute…NCT07616921 · Not applicable · University of Washington · starts Dec 1, 2026
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaNCT07645469 · Phase 1 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNCT07617363 · Phase 1 · Washington University School of Medicine · starts Nov 30, 2026
- Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT07783100 · Phase 2 · The First Affiliated Hospital of Xiamen University · starts Nov 11, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic…NCT07582172 · Phase 2 · City of Hope Medical Center · starts Nov 5, 2026
- A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML)…NCT07925190 · Phase 3 · Beijing InnoCare Pharma Tech Co., Ltd. · starts Nov 3, 2026
- Efficacy of Asciminib in Chronic Phase CML Patients With T315I MutationsNCT07789574 · Phase 2 · Thomas Ernst, Prof. Dr. med. · starts Nov 1, 2026
- Allogeneic iNKT Cell Therapy (agenT-797) After SCTNCT07758218 · Phase 1 · University of Wisconsin, Madison · starts Nov 1, 2026
Trials Authorized in Canada
The 10 newest of 114; search them all in Canada trials| Oct 14, 2026 | A phase I/ib, multi-center, open-label, dose escalation and dose expansion study of fvy281 as monotherapy in adult participants with relapsed/refractory acute…FVY281 / AZACITIDINE | Novartis Pharmaceuticals Corporation | Pending |
| Sep 29, 2026 | A two-part, phase 2b/phase 3 double-blinded, randomized study of ipn60340 in combination with azacitidine and venetoclax versus placebo in combination with…IPN60340 | Ipsen | Pending |
| Sep 25, 2026 | A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…VICRIMENIB (S243249, BN104) | Servier | Pending |
| May 27, 2026 | A phase 1b study of the safety and pharmacokinetics of pivekimab sunirine in pediatric subjects with relapsed or refractory acute myeloid leukemia (aml)PIVEKIMAB SUNIRINE (IMGN-632) | AbbVie | Pending |
| May 26, 2026 | A phase 2 trial of gilteritinib in combination with azacitidine and venetoclax to overcome venetoclax resistance in patients with relapsed/refractory flt3-wild…GILTERITINIB | BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY | Pending |
| Apr 1, 2026 | A phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and efficacy of tern-701 in participants with chronic myeloid leukemiaTERN-701 | TERNS, INC. | Pending |
| Mar 26, 2026 | A randomized phase II study of venetoclax and hma-based therapies for the treatment of older and unfit adults with newly diagnosed flt3-mutated acute myeloid…VENETOCLAX (ABT-199) / GILTERITINIB (ASP2215) | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
| Dec 15, 2025 | A phase 3, randomized, double-blind, placebo-controlled study of revumenib in combination with intensive chemotherapy in participants with newly diagnosed aml…REVUMENIB (SNDX-5613) / CYTARABINE / DAUNORUBICIN / IDARUBICIN | Syndax Pharmaceuticals | Pending |
| Aug 28, 2025 | Phase 3 randomized, double-blind, placebo-controlled studies assessing ziftomenib in combination with either standard of care nonintensive…ZIFTOMENIB / VENETOCLAX / AZACITIDINE / DAUNORUBICIN / CYTARABINE | Kura Oncology | Ongoing |
| May 23, 2025 | A phase 1 study of tak-243 for relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes with increased blastsTAK-243 | UNIVERSITY HEALTH NETWORK | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 206| May 29, 2026 | Cavhanzatreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Cycle Pharmaceuticals Ltd | Approved |
| May 13, 2026 | Inqoviin combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have… | Taiho Oncology Inc. | Approved |
| Nov 13, 2025 | Komziftitreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who… | Kura Oncology, Inc. | Approved |
| Oct 24, 2025 | Revuforjtreatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric… | Syndax Pharmaceuticals, Inc. | Approved |
| Aug 1, 2025 | Phyragotreatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in… | Handa Therapeutics, LLC | Approved |
| Jan 21, 2025 | Grafapexin combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric… | Medac GmbH | Approved |
| Nov 15, 2024 | Revuforjtreatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric… | Syndax Pharmaceuticals, Inc. | Approved |
| Nov 7, 2024 | Danzitentreatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; and… | Azurity Pharmaceuticals, Inc. | Approved |
| Oct 29, 2024 | Scemblixtreatment of adult patients with previously treated Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 29, 2024 | Scemblixtreatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) | Novartis Pharmaceuticals Corporation | Approved |
| Dec 5, 2023 | Phyragotreatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase;… | Handa Therapeutics, LLC | Approved |
| Jul 20, 2023 | Vanflytain combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following… | Daiichi Sankyo, Inc. | Approved |
| Dec 1, 2022 | Rezlidhiatreatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1)… | Rigel Pharmaceuticals, Inc. | Approved |
| May 25, 2022 | TibsovoIn combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible… | Servier Pharmaceuticals LLC | Approved |
| Oct 29, 2021 | ScemblixTreatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously… | Novartis Pharmaceuticals Corporation | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA